What You Can Learn From Charles River Holders Who Are Up 64%
Charles River Laboratories International (NYSE:CRL) stock has seen a 63.6% gain over the past year, trading now at US$290. This significant increase reflects investor optimism that the company's focus on New Approach Methods and AI-enabled services will offset regulatory pressures on traditional animal testing. However, recent financial data shows a decline in Q2 2026 revenue and a net loss, suggesting that the "turnaround pitch" is still a work in progress rather than a proven success.
IDEXX Laboratories stock heads toward November 2 results
IDEXX Laboratories (IDXX) stock is heading towards its Q3 2026 earnings release on November 2, 2026. The company's Q2 2026 adjusted EPS of $4.27 beat the consensus of $3.94, and investors will be looking to see if this earnings conversion continues. Analysts currently have a "Moderate Buy" consensus with an average 12-month price target of $747.00, though the stock remains significantly below its 52-week high.
Charles River Laboratories (CRL) EVP & CFO Glenn Coleman Buys 10 Shares
Glenn Coleman, EVP & CFO of Charles River Laboratories International Inc. (CRL), purchased 10 shares of the company's stock on September 30, 2026. This small insider buy is seen as a positive signal, though it contrasts with a broader trend of more insider selling than buying at the company over the past year. The stock is currently deemed "Significantly Overvalued" by GuruFocus based on its GF Value.
Charles River Laboratories International Inc. Research & Ratings | CRL
This article provides detailed research and ratings for Charles River Laboratories International Inc. (CRL), including analyst ratings, stock grader sentiment, key financial metrics, peer comparisons, and earnings estimates. It shows an average price target of $316.67 from 21 ratings, with a consensus of "Buy," and outlines past and projected quarterly and yearly earnings.
Is Charles River Laboratories International (CRL) Fairly Valued Or Is More Upside Left?
Charles River Laboratories International (CRL) is currently trading slightly below its average analyst target and close to its intrinsic value, with a "most followed narrative" pegging its fair value at $305.00, suggesting it is 5% undervalued. The company's investments in new methodologies and digitalization are seen as mitigating risks and supporting future margins, despite potential pressures from weak R&D funding or a shift away from animal testing. A discounted cash flow model suggests its future cash flows are just below its current share price, indicating a narrow margin of safety.
An employee stock plan purchase adds 10 shares for Charles River (CRL) CFO Glenn Coleman.
Charles River Laboratories International, Inc. CFO Glenn Coleman purchased 10 shares of common stock at $297.43 per share on September 30, 2026, through the company's Employee Stock Purchase Plan. This purchase increased his direct holdings to 27,762 shares. The transaction was made during an open trading window and did not involve a Rule 10b5-1 plan.
IQVIA Holdings Inc. (IQV) stock price, news, quote and history - Yahoo Finance
This Yahoo Finance page provides a comprehensive overview of IQVIA Holdings Inc. (IQV) stock, including its current price, recent news headlines, and historical performance data. It highlights that the stock closed at $258.21, with various news articles discussing its valuation, recent gains, and strategic moves like pricing $2 billion in notes. The performance overview shows that IQVIA has outperformed the S&P 500 year-to-date and over the past year.
Chemed Corporation (CHE) stock price, news, quote and history
This article provides a comprehensive overview of Chemed Corporation (CHE), including its current stock price, recent performance metrics, and key financial data. It details the company's business segments, VITAS and Roto-Rooter, and highlights analyst ratings and price targets. The information presented aims to give investors a snapshot of CHE's market position and operational details.
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
The article reviews the Q2 performance of several drug development inputs & services stocks, highlighting West Pharmaceutical Services (WST) as a strong performer. It details the revenue and EPS beats for companies like Azenta (AZTA), IQVIA (IQV), Charles River Laboratories (CRL), and Repligen (RGEN), noting their individual strengths and market reactions to their earnings reports. The industry as a whole saw strong Q2 results, with revenues beating estimates and share prices performing well post-earnings.
Charles River Laboratories International, Inc. (CRL) latest stock news and headlines
This article provides the latest news and headlines for Charles River Laboratories International, Inc. (CRL), including stock performance data and recent press releases. Key news items cover strategic business reports on the animal model and pharmaceutical impurity synthesis markets, as well as partnerships and investor day highlights. The company's stock shows a YTD return of +43.79% against the S&P 500's +11.99%.
Charles River Laboratories Stock: Company Reaffirms 2026 Guidance and Sets 2030 Targets
Charles River Laboratories International, Inc. reaffirmed its 2026 financial guidance at the upper end of previous ranges during its Investor Day on September 24, 2026, citing continued favorable demand. The company also introduced long-term financial targets through 2030, including organic revenue growth and a non-GAAP operating-margin target. These targets are based on its "Pathway to Purpose" strategy and "Create the Future" program.
UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175
UBS has upgraded Charles River Laboratories International (CRL) to a "Buy" rating from "Neutral." The firm also significantly increased its price target for CRL shares, moving it to $357 from the previous target of $175. This positive revision indicates UBS's increased confidence in the company's future performance.
UBS resumes Charles River Labs stock coverage with buy rating By Investing.com
UBS has resumed coverage of Charles River Laboratories International Inc. (NYSE:CRL) with a buy rating and a price target of $357.00, citing the market's undervaluation of the positive impact from internalizing non-human primate supply. The firm anticipates significant cost savings and strong growth fueled by a recovery in biotech end markets. This positive outlook is echoed by other analysts, with several firms upgrading ratings and raising price targets for Charles River Labs.
UBS resumes Charles River Labs stock coverage with buy rating
UBS has resumed coverage of Charles River Laboratories International Inc. (NYSE:CRL) with a buy rating and a price target of $357.00. The firm believes the market is underestimating the positive impact of internalizing non-human primate supply on earnings and that medium-term growth estimates are too low given the strong recovery in biotech markets. Other analysts like JPMorgan, Jefferies, and TD Cowen have also shown positive outlooks for the company.
Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & History
This Yahoo Finance article provides a detailed overview of Medpace Holdings, Inc. (MEDP), including its stock price, historical performance, key financial metrics, and analyst ratings. It highlights the company's role as a clinical research organization offering drug and medical device development services globally. The article also presents performance comparisons against the S&P 500 and recent earnings trends.
PMGC Subsidiary NorthStrive Biosciences Engages Charles River Laboratories for Analytical Characterization of EL-22 and EL-32 Programs
NorthStrive Biosciences, a subsidiary of PMGC, has partnered with Charles River Laboratories for the analytical characterization of its EL-22 and EL-32 drug programs. This collaboration aims to advance the development of these programs by leveraging Charles River's expertise in biologics characterization. The engagement signifies a significant step for NorthStrive in bringing its therapeutic candidates closer to clinical stages.
NorthStrive Biosciences Partners with Charles River
NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., has partnered with Charles River Laboratories to advance its EL-22 and EL-32 engineered probiotic programs. This collaboration aims to strengthen the analytical foundation for these programs by characterizing plasmid copy numbers, moving them towards an IND-enabling development framework. The partnership builds on NorthStrive's efforts to develop its engineered probiotic platform, particularly for muscle preservation, including for patients on GLP-1 weight loss treatments.
Charles River Laboratories stock pre-market as Cooke & Bieler cites demand stabilization
Charles River Laboratories stock is gaining pre-market attention after Cooke & Bieler highlighted the company in its second-quarter 2026 investor letter. The investment manager cited stabilizing demand for the company's services following a period of cyclical contraction, referencing better-than-expected first-quarter earnings as evidence. Charles River Laboratories International trades on the New York Stock Exchange under the ticker CRL.
Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth.
The global computer-aided drug discovery (CADD) market is projected to grow from $3.2 billion in 2025 to $6.7 billion by 2032, driven by an 11% CAGR. This growth is fueled by advancements in AI, machine learning, cloud computing, and multi-omics, which are accelerating drug discovery, reducing costs, and enabling personalized therapies. The report details market trends, growth drivers, and segmented forecasts, highlighting key players like Bayer and Charles River Laboratories.
Medpace Holdings, Inc. (MEDP) latest stock news and headlines
This article provides a compilation of recent news and headlines regarding Medpace Holdings, Inc. (MEDP), showcasing its stock performance and various analyst opinions. It highlights MEDP's recent market outperformance and upcoming financial results announcement, while also featuring comparisons with other stocks and discussions on its valuation.
Return on invested capital % of Charles River Laboratories International, Inc. – HAN:RV6
This page displays the Return on Invested Capital (ROIC) percentage for Charles River Laboratories International, Inc., traded under the ticker HAN:RV6 on the Hannover Stock Exchange. The financial data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The primary content of the article focuses on presenting this specific financial metric without further descriptive analysis or discussion.
Charles River Laboratories International, Inc. Cash Flow – HAN:RV6
This article provides financial data for Charles River Laboratories International, Inc. (HAN:RV6), focusing on its cash flow. It highlights free cash flow for Q2 2026 at 130.13M EUR and for 2025 at 441.46M EUR, with operating cash flow for 2025 at 628.05M EUR. The data includes operating, investing, and financing activities over several years.
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
NorthStrive Biosciences, a subsidiary of PMGC Holdings (ELAB), has partnered with Charles River Laboratories to conduct analytical testing for its engineered probiotic programs, EL-22 and EL-32. This collaboration aims to characterize plasmid copy numbers in the bacterial product candidates to support product identity, manufacturing consistency, and comparability as they advance towards IND-enabling development. The ultimate goal is to develop a platform addressing muscle health, particularly for patients using GLP-1 receptor agonists for weight loss.
PMGC Subsidiary NorthStrive Biosciences Engages Charles River Laboratories for Analytical Characterization of EL-22 and EL-32 Programs
PMGC Holdings Inc. announced that its subsidiary, NorthStrive Biosciences, has partnered with Charles River Laboratories for analytical characterization of its engineered probiotics EL-22 and EL-32. These probiotics are being developed for muscle preservation, particularly for patients undergoing weight loss treatments. The collaboration focuses on specialized testing, including plasmid copy number analysis, to strengthen NorthStrive's understanding of product characteristics and support future regulatory approvals and manufacturing scalability.
Charles River Labs Q3 Results: Adj EPS Expected At $2.90 - $3.00
Charles River Laboratories expects adjusted earnings per share (EPS) of $2.90-$3.00 for Q3, facing challenges from lower North American research model volumes due to flat NIH budgets and slow grant processing. Despite these operational headwinds, the company plans to continue its acquisition strategy to drive future growth.
Charles River Laboratories stock trades near a yearly high as targets rise
Charles River Laboratories (CRL) stock is trading near its 52-week high despite a reported decline in Q2 revenue and a GAAP net loss. Several analysts, including Mizuho, JPMorgan, TD Cowen, and Robert W. Baird, have raised their price targets for CRL, indicating confidence in its long-term prospects. The company has also reaffirmed its 2026 organic revenue growth guidance and increased its non-GAAP EPS outlook, while projecting significant savings and growth for 2027-2030.
Charles River Laboratories stock at USD 294.59 on September 28, 2026
Charles River Laboratories (CRL) shares closed at USD 294.59 on September 28, 2026, up 0.60 percent. The company reaffirmed its 2026 financial guidance at its Investor Day, expecting organic revenue growth and non-GAAP earnings per share at the upper end of previous ranges. Additionally, CRL introduced long-term targets for 2030, including a non-GAAP operating margin of 21.00 percent to 21.30 percent and significant cumulative savings from its "Create the Future" program.
CRL.GD Bond Profile: Coupon and Redemption
This article provides a detailed profile of the CRL.GD bond issued by CRA International, Inc. It covers key facts such as issuer information, issue and maturity dates, face value, and classification details. The profile also outlines the bond's coupon payment schedule, including upcoming payouts, and redemption information.
Should Long Term Growth Targets Require Action From Charles River Labs Stock Investors?
Charles River Laboratories International recently presented long-term growth targets, including 5% to 7% organic revenue growth and low double-digit non-GAAP EPS growth, driven by AI and automation. These initiatives, particularly its rapid cell banking launch, are expected to generate significant savings and strengthen its Manufacturing Solutions mix. Investors are urged to assess the company's execution on these complex platforms and consider both optimistic and cautious analyst perspectives on future growth and potential downsides.
Is Charles River Laboratories Stock Outperforming the S&P 500?
Charles River Laboratories (CRL) stock has significantly outperformed the S&P 500 year-to-date and over the past year, driven by strong earnings and an optimistic future outlook. The company, a large-cap contract research organization, reported better-than-expected Q2 2026 results and raised its full-year EPS guidance, also projecting robust organic revenue growth and efficiency savings through 2030. Analysts maintain a "Strong Buy" rating for CRL.
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
CareDx (CDNA) shares surged 13% after BTIG raised its price target to $74 from $60, maintaining a Buy rating. The company reported a 52% year-over-year revenue increase in Q2 2026, driven by a 61% growth in Testing services. While earnings and revenue growth are positive, investors should monitor trends in earnings estimate revisions as the stock currently holds a Zacks Rank #2 (Buy).
Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating
Barclays has increased its price target for Charles River Laboratories International (NYSE: CRL) to $330 from $300, while maintaining an Overweight rating on the stock. This adjustment reflects a positive outlook from the firm regarding the company's future performance.
Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO
City Therapeutics, an RNAi biotech co-founded by Alnylam founder Maraganore, has filed for an initial public offering (IPO) on Nasdaq under the ticker CTY. The company, which has raised approximately $238.8 million since its launch in October 2024, currently employs 81 people and has established partnerships with Bausch + Lomb and Biogen. The IPO aims to build on the success of Alnylam Pharmaceuticals Inc.
Qiagen N.V. (QGEN) Stock Price, News, Quote & History
This article provides a detailed financial overview of Qiagen N.V. (QGEN), including its current stock price, historical performance, key financial metrics, and analyst recommendations. It outlines the company's business in diagnostics and research, offering various sample to insight solutions globally. The report also highlights recent earnings, performance against benchmarks, and important valuation measures.
Charles River Laboratories International, Inc. (CRL) Latest Stock News & Headlines - Yahoo Finance
This Yahoo Finance page provides the latest news and headlines for Charles River Laboratories International, Inc. (CRL), including articles on its stock performance, market forecasts for contract research organization and drug safety services, and the company's strategic vision. It also displays real-time stock quotes, recent performance data, and related news from various financial sources.
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About?
Celldex Therapeutics, Inc. (CLDX) is drawing market attention after its barzolvolimab studies in chronic spontaneous urticaria met primary and key secondary endpoints. This development highlights the company's operating priorities and its position within the Healthcare Stocks sector. Investors are now focused on consistent execution and how these positive clinical results translate into sustained operational success and customer response.
AngloGold Ashanti Appoints Paul Graves as Independent Non-Executive Director
AngloGold Ashanti plc has announced the appointment of Paul Graves, former Rio Tinto Lithium CEO, as an independent non-executive director, effective October 1, 2026. Graves brings over three decades of experience in natural resources, finance, and public company leadership, and will also serve on the company’s Audit and Risk Committee and its Social, Ethics and Sustainability Committee. His extensive background, including roles at Goldman Sachs and as CEO of Livent Corporation and Arcadium Lithium, will provide valuable expertise in capital allocation, risk management, and market dynamics, particularly in commodities tied to electrification.
Mizuho raises Charles River Labs stock price target to $295 on outlook
Mizuho increased its price target for Charles River Laboratories International Inc. (NYSE:CRL) to $295 from $264, while maintaining a Neutral rating, following the company's Investor Day. The upward adjustment reflects Mizuho's increased confidence in the durable recovery of biopharma demand and the company's potential for sustainable growth, as the new financial targets exceeded expectations. Despite the positive outlook and strong past performance, Mizuho kept a Neutral rating due to valuation concerns, as InvestingPro analysis suggests the stock is currently overvalued.
Coca-Cola’s Secret Dividend Weapon Is a Business Model Most Investors Overlook
Coca-Cola's consistent dividend growth for over 60 years is attributed to its asset-light business model, primarily selling concentrate and syrup to bottlers, which results in high gross margins and strong free cash flow. This model allows KO to comfortably cover its substantial dividend payments, unlike peers PepsiCo and Keurig Dr Pepper who have heavier reinvestment burdens. While the free cash flow coverage is robust, investors should monitor the company's relatively high earnings-based payout ratio and projected EPS growth for future dividend sustainability.
RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating
RBC has increased its price target for Charles River Laboratories International (CRL) to $322 from $282, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the biotechnology and medical research company. The article also notes other recent analyst actions, mostly showing increased price targets for CRL.
Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating
Evercore ISI has increased its price target for Charles River Laboratories International (CRL) to $330 from $320, while reaffirming an Outperform rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the biotechnology and medical research company. The news comes alongside several other analyst adjustments for Charles River Laboratories, indicating active re-evaluation by financial institutions.
Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating
Barclays has increased its price target for Charles River Laboratories International (CRL) to $330 from $300, while maintaining an "Overweight" rating on the stock. This adjustment reflects a positive outlook from the analyst firm for the biotechnology and medical research company. The news comes alongside similar price target adjustments from other analysts like Mizuho, TD Cowen, and Baird, indicating broader analyst confidence in CRL's performance.
A former Rio Tinto Lithium chief executive is set to join AngloGold Ashanti (AU)'s board.
AngloGold Ashanti plc announced the appointment of Paul Graves, former Chief Executive of Rio Tinto Lithium, as an independent non-executive director, effective October 1, 2026. Graves brings over 30 years of experience in natural resources, finance, and public-company leadership, including roles at Livent Corporation, FMC Corporation, and Goldman Sachs. He will serve on the Audit and Risk Committee and the Social, Ethics and Sustainability Committee, adding significant value to AngloGold Ashanti's long-term strategy.
Mineralys Therapeutics (NasdaqGS:MLYS) Stock Price
Mineralys Therapeutics (MLYS) is highlighted as potentially undervalued, with analyst fair value estimates ranging from $31.65 to $56, suggesting significant upside. The company is advancing lorundrostat, an aldosterone synthase inhibitor, for hypertension and cardiorenal conditions, with promising late-stage clinical trial data and an upcoming late-breaking presentation at the American Heart Association Scientific Sessions. Despite recent net losses, the company is well-funded with $661M in cash, positioning it for a strong commercial launch of lorundrostat following an anticipated FDA approval.
AngloGold Ashanti Plc Announces Appointment of Non-Executive Director
AngloGold Ashanti Plc (NYSE: AU; JSE: ANG) announced the appointment of Paul Graves as an independent non-executive director, effective October 1, 2026. Mr. Graves brings over 30 years of experience in natural resources, finance, and public company leadership, having previously served as CEO of Rio Tinto Lithium and Livent Corporation. He will join the Audit and Risk Committee and the Social, Ethics and Sustainability Committee.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : TD COWEN RAISES TARGET PRICE TO $325 FROM $300
TD Cowen has increased its target price for Charles River Laboratories International, Inc. (CRL.N) to $325 from $300. This update indicates a more positive outlook from the financial firm regarding the company's future stock performance. The news was reported by Reuters.
H.B. Fuller Releases Q3 2026 Financial Results
H.B. Fuller Company reported strong third-quarter 2026 financial results, exceeding Wall Street expectations with adjusted earnings of $1.52 per share on revenue of $938.2 million. The company saw organic revenue growth of 4.4% and an overall revenue increase of 5.2% year-over-year. Management provided full-year adjusted EPS guidance between $4.70 and $4.85, reflecting continued confidence in the adhesives market.
Charles River Laboratories International Jumps 5.1% in Broad Rally
Charles River Laboratories International (CRL) saw its stock surge 5.1% to $291.40, part of a broad rally across the diagnostics and research sector. This movement, echoed by peers like Revvity and Thermo Fisher, suggests investor optimism for the broader healthcare and research space rather than company-specific news. Investors are advised to monitor sector trends and potential catalysts for sustained momentum.
Charles River Laboratories rises after reaffirming 2026 outlook and unveiling 2030 targets
Charles River Laboratories International (CRL) saw its stock rise 5.2% after reaffirming its 2026 revenue and non-GAAP EPS outlook to the upper ends of previous guidance ranges. The company also introduced new long-term targets for 2030, including accelerated organic growth, margin expansion, and a significant cost-savings plan through its "Create the Future" program. These strategic updates and positive financial outlook appear to have been well-received by investors.
Agilent Technologies stock hits 52-week high at 169.07 USD
Agilent Technologies (NYSE: A) stock recently hit a 52-week high of $169.07, demonstrating significant investor confidence and strong market performance with a 37.56% increase over the past year and a 45.37% return in six months. This surge is supported by 11 analysts revising earnings upwards and stronger-than-expected fiscal third-quarter results, prompting raised price targets from multiple firms. Despite these positive indicators, InvestingPro data suggests the stock might be overvalued relative to its Fair Value estimate.
